Free shipping on orders over $149
SafeRxPills - Online Pharmacy
These products are intended for personal use only. We are not licensed by the FDA.

Forxiga 10mg

Generic: Dapagliflozinby AstraZeneca Pharma India Ltd

Buy Forxiga 10mg (Dapagliflozin) online | SafeRxPills

Strength

Select pack size

1
Free shipping over $149
Free reshipment if lost
Discreet packaging
WHO-GMP certified
Secure checkout

Similar medicines

View all
Buy Oxra-L Tablet (Dapagliflozin/Linagliptin) online | SafeRxPills

Oxra-L Tablet

$53.00View
Buy Vysov D 100/5 (Vildagliptin/Dapagliflozin) online | SafeRxPills

Vysov D 100/5

$60.00View
Buy Amaryl 1mg (Glimepiride) online | SafeRxPills

Amaryl 1mg

$31.00View
Buy Amaryl 2mg (Glimepiride) online | SafeRxPills

Amaryl 2mg

$37.00View

About Forxiga 10mg

Forxiga 10mg is AstraZeneca's dapagliflozin 10 mg tablet, sold here in its Indian pack; Tata 1mg, PharmEasy and Medkart all name AstraZeneca (AstraZeneca Pharma India Ltd) as the company. In the US the same medicine is sold as Farxiga; Forxiga is the brand name in the UK, Europe, Australia, Canada and India. Dapagliflozin is an SGLT2 inhibitor: it blocks SGLT2, the kidney transporter responsible for most of the reabsorption of filtered glucose, so more glucose leaves the body in the urine; it also reduces sodium reabsorption (US label 12.1). It is taken as one tablet once a day. In the US label, 10 mg is the dose for chronic kidney disease, heart failure and lowering the risk of heart failure admission in type 2 diabetes, and the top dose for blood glucose control. We sell Forxiga 10mg in packs of 28, 56 and 84 tablets, from $2.54 a tablet in the 84 pack.

Three points first. Dapagliflozin needs a doctor: a kidney function and fluid check before you start, a plan for sick days and surgery, and a review of any insulin or sulfonylurea you take with it. Two warnings matter most: ketoacidosis, which can happen even when blood glucose is not very high, and serious genital and urinary infections, including Fournier's gangrene. And on price, plainly: The FDA approved the first US generic dapagliflozin tablets on 7 April 2026, generics are now on sale, and US pharmacies now pay about 18 cents for a generic 10 mg tablet. If you are in the US with a prescription, a local generic is very likely to cost you less than our tablets. This page uses the current US Farxiga label and the UK Forxiga 10 mg product information, both listed at the end.

Forxiga 10mg at a glance

Active ingredientDapagliflozin 10 mg per film-coated tablet (as dapagliflozin propanediol), an SGLT2 inhibitor
Brand and makerForxiga, AstraZeneca. Tata 1mg names AstraZeneca as marketer; PharmEasy and Medkart name AstraZeneca Pharma India Ltd. Tata 1mg and PharmEasy give the United States as the country of origin; Medkart gives India
Regulatory statusDapagliflozin is licensed in the US (Farxiga and generics), the UK (Forxiga, POM), Australia (Forxiga, Schedule 4) and Canada (Forxiga, prescription). This Indian Forxiga pack is not registered with the FDA, MHRA, TGA or Health Canada
Usual dose from the labelUS: 10 mg once daily for kidney disease, heart failure and heart failure risk reduction (2.3); for glucose control start at 5 mg and increase to 10 mg if needed (2.2). UK: 10 mg once daily for all three uses (4.2). With or without food
Half-lifeAbout 12.9 hours after a 10 mg dose; peak blood level usually within 2 hours when fasting (US label 12.3)
Packs28, 56 and 84 tablets. Indian strips hold 14 tablets (Tata 1mg, PharmEasy, Medkart); the carton in our product photo says 2 x 14 tablets
Price per tablet$3.14 (28 pack), $2.82 (56 pack), $2.54 (84 pack), before shipping
Delivery7 to 14 business days to the US, UK, Australia and Canada; $25 shipping under $149, free from $149

What Forxiga 10mg is licensed for

US label (section 1). Farxiga is indicated:

  • "To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression."
  • "To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure."
  • "To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors."
  • "As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus."

US limitations of use. Farxiga "is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus". It is not recommended for glucose control in type 2 diabetes with an eGFR below 45 mL/min/1.73 m2, where it "is likely to be ineffective". It is not recommended for chronic kidney disease in people with polycystic kidney disease, or in people who need or recently had immunosuppressive therapy for kidney disease.

UK label (section 4.1). Adults and children aged 10 and above with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise, "as monotherapy when metformin is considered inappropriate due to intolerance" or "in addition to other medicinal products for the treatment of type 2 diabetes"; adults with "symptomatic chronic heart failure"; and adults with "chronic kidney disease".

Type 1 diabetes. Dapagliflozin is not a type 1 diabetes medicine in either label. The US label says it "significantly increases the risk of diabetic ketoacidosis, a life-threatening event" in type 1 diabetes and "is not indicated for glycemic control" there (5.1). The UK label says it "should not be used for treatment of patients with type 1 diabetes" (4.4).

Heart failure and kidney disease use does not require diabetes. In DAPA-HF 42% and in DELIVER 45% of patients had a history of type 2 diabetes (UK 5.1), and in DAPA-CKD 68% had type 2 diabetes (US 14.4).

Price per tablet

Prices below are as of November 2026; the pack selector shows the current price.

PackPricePer tabletShippingPer tablet with shipping
28 tablets$88$3.14$25$4.04
56 tablets$158$2.82Free$2.82
84 tablets$213$2.54Free$2.54

The 28 pack is under the $149 free shipping line, so it carries $25 shipping; the 56 and 84 packs ship free. The larger packs are also cheaper per tablet before shipping.

How long a pack lasts. At one 10 mg tablet a day, the 28 pack lasts 4 weeks, the 56 pack 8 weeks and the 84 pack 12 weeks (our arithmetic; these are one, two and three Indian cartons of 2 x 14). If you take dapagliflozin for glucose control only, a US doctor may start you on 5 mg (US 2.2), so agree the dose before buying a large pack, and check that the expiry date on the strips covers the months you need.

Compared with Farxiga and US generic dapagliflozin

Forxiga 10mg (ours, Indian pack)US Farxiga 10 mgUS generic dapagliflozin 10 mg
MakerAstraZeneca (Indian pack)AstraZenecaMany US generic makers
FDA statusNot registered with the FDA (Indian pack)Approved (NDA 202293, 8 January 2014)Approved generics; first approved 7 April 2026
Cost per tablet$2.54 to $3.14 before shippingNADAC $12.07647NADAC $0.18445
Cost of 28 tablets$88 before shippingAbout $338.14 at NADACAbout $5.16 at NADAC

NADAC is the average price US pharmacies pay to buy a medicine, published by the US Medicaid programme. It is not the price a patient pays at the counter. In the NADAC file as of 4 November 2026, all three Farxiga 10 mg NDC rows (bottles of 30 and 90 and the 3 x 10 blister carton) are at $12.07647 a tablet, effective 21 October 2026. All 21 generic dapagliflozin 10 mg NDC rows are at $0.18445 a tablet, effective 21 October 2026 (one row 28 October 2026). For Medicare Part D, CMS set a negotiated price of $178.50 for a 30-day supply of Farxiga from 1 January 2026, against a 2023 list price of $556.00; what a patient pays depends on the plan.

Say it plainly: US generics are far cheaper than ours. Our tablet costs about 14 to 17 times what US pharmacies pay for generic dapagliflozin 10 mg, before our shipping, and about a fifth to a quarter of the Farxiga brand cost (our arithmetic). If you live in the US and have a prescription, compare local cash prices for generic dapagliflozin before you order from us.

One difference in the US generic labels. The FDA said the first generics were approved for glucose control in adults with type 2 diabetes and to reduce the risk of heart failure admission in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. The current Teva and Lupin generic labels we checked list only those two uses; they do not list the kidney disease or heart failure indications, or use in children (the Teva label says the children's information is left out because of AstraZeneca's marketing exclusivity). Ask your doctor or pharmacist what this means for your prescription.

UK and India. In the UK, generic dapagliflozin is on the NHS Drug Tariff (Category M). The Drug Tariff price for a 28 tablet pack of dapagliflozin 10 mg is £2.32 from 1 October 2026 (NHSBSA dm+d), down from £36.59 before dapagliflozin moved into Category M in September 2025. That is what the NHS pays pharmacies, not a retail price. In India, generic dapagliflozin is sold by many companies. We also list two Indian generics: Sun Pharma's Oxra 10mg at $1.25 a tablet in its 28 pack, and Healing Pharma's Dapasmart 10mg at $0.35 a tablet in its 100 pack, both before shipping (as of November 2026). We have not seen bioequivalence data comparing them with Forxiga.

Is our Forxiga the same as Farxiga? It is the same brand from the same company, with the same active ingredient and strength. The Indian pack is not registered with the FDA, MHRA, TGA or Health Canada, so we cannot point to a review of this pack by any of them. The US and UK labels describe the 10 mg tablet as yellow, diamond-shaped and film-coated, engraved "10" on one side and "1428" on the other (US 3; UK 3); we have not confirmed the markings on the Indian tablets.

Which strength to choose

Daily doseProductHow it fits the labels
5 mg once dailyForxiga 5mgUS: the recommended starting dose for glucose control in type 2 diabetes, adults and children aged 10 and over (2.2). UK: the starting dose in severe liver impairment, raised to 10 mg if well tolerated (4.2). Not a US or UK dose for heart failure or kidney disease
10 mg once dailyForxiga 10mg (this product)US: the dose for kidney disease, heart failure and heart failure risk reduction in type 2 diabetes (2.3), and the dose after 5 mg if more glucose control is needed (2.2). UK: the recommended dose for type 2 diabetes, heart failure and kidney disease (4.2)
Above 10 mgNoneAbove the labelled maximum. The US label describes 150 mg as 15 times "the recommended maximum dose", which makes 10 mg the maximum (12.2)

In a 24 week US monotherapy trial, 10 mg lowered HbA1c by 0.7 points more than placebo and 5 mg by 0.5 points; 50.8% on 10 mg and 44.2% on 5 mg reached an HbA1c below 7%, against 31.6% on placebo (US Table 7). Glucose lowering depends on the kidneys: the UK label says it is reduced when eGFR is below 45 and "is likely absent in patients with severe renal impairment" (4.2). Moving between strengths is your doctor's decision; never raise the dose yourself.

Dapagliflozin also comes combined with a DPP-4 inhibitor in Oxra-L (dapagliflozin 10 mg with linagliptin 5 mg) and Vysov D (vildagliptin 100 mg with dapagliflozin 5 mg). These are different products with their own dosing; do not swap one for another without your doctor.

How to take Forxiga 10mg

  1. Take one tablet once a day, with or without food (US 12.3; US Medication Guide). The UK label says it can be taken at any time of day and the tablet is to be swallowed whole (4.2).
  2. Your doctor should check your kidney function and fluid status before you start, and correct any fluid loss first (US 2.1).
  3. If you miss a dose, take it as soon as you remember; if it is almost time for the next dose, skip the missed one. Do not take two doses at the same time (US 2.5; US Medication Guide).
  4. Drink enough fluid. The US label says dehydration may increase the risk of low blood pressure (17). The US Medication Guide says call your healthcare provider right away if you eat or drink less than usual, or lose fluid from vomiting, diarrhoea or too much time in the sun.
  5. Before surgery or a procedure with prolonged fasting, the US label says withhold it "for at least 3 days, if possible", and resume when you are clinically stable and eating and drinking again (2.4). The UK label says treatment should be interrupted in people admitted for major surgery or acute serious illness (4.4). Tell the surgical team you take it.
  6. Expect a positive urine glucose test. Urine glucose tests and the 1,5-AG blood test are not reliable for checking diabetes control while you take it (US 7; UK 4.4, 4.5).
  7. If you have diabetes, look after your feet. The UK label notes more toe amputations in long-term studies with SGLT2 inhibitors and says counselling on "routine preventative foot care" is important (4.4).
  8. Never start, stop or switch diabetes, heart or kidney medicines on your own.

Kidney function and other groups needing care

  • Kidney function, US label. Glucose control: same dose with an eGFR of 45 or more; not recommended below 45 (2.2). Kidney disease, heart failure and heart failure risk reduction: same dose with an eGFR of 25 or more; "Initiation with FARXIGA is not recommended in patients with an eGFR less than 25"; if the eGFR falls below 25 during treatment, patients "may continue FARXIGA 10 mg orally once daily" to reduce the risk of eGFR decline, end-stage kidney disease, cardiovascular death and heart failure admission (2.3). The trials did not enrol people with an eGFR below 25 or on dialysis (8.6). In one trial of people with diabetes and an eGFR of 30 to below 60, 13 people on Farxiga had bone fractures against none on placebo (8.6).
  • Kidney function, UK label. No dose change based on kidney function; starting it with an eGFR below 15 is not recommended, and experience with starting it below an eGFR of 25 is limited (4.2, 4.4). If eGFR falls below 45 in type 2 diabetes, additional glucose lowering treatment should be considered (4.2). The two labels set different starting thresholds (US 25, UK 15); your doctor decides.
  • Early creatinine rise. Starting an SGLT2 inhibitor causes a small rise in creatinine and fall in eGFR, generally within two weeks, which then stabilises; changes that do not fit this pattern need checking for acute kidney injury (US 6.1).
  • Insulin or a sulfonylurea. A lower dose of these may be needed (US 5.4, 7; UK 4.2). In the add-on to glimepiride trial, glucose below 54 mg/dL occurred in 3.3% on 10 mg against 0.7% on placebo; with metformin and a sulfonylurea, 6.4% against 2.8% (US Table 3).
  • Age 65 and over, low blood pressure, diuretics. People with an eGFR below 60, elderly people and people on loop diuretics may be at increased risk of fluid loss or low blood pressure; volume status and kidney function should be checked before starting (US 5.2). The UK label asks for caution where a fall in blood pressure could be a risk, such as people on blood pressure medicines with a history of low blood pressure, and elderly people (4.4).
  • Liver impairment. US: no dose change, but in severe impairment the benefit and risk "should be individually assessed" (8.7). UK: in severe hepatic impairment "a starting dose of 5 mg is recommended", then 10 mg if well tolerated (4.2), so Forxiga 10mg is not the UK starting product for this group.
  • Heart failure NYHA class IV. The UK label says experience is limited (4.4).
  • Children. Glucose control use is licensed from age 10 (US 8.4; UK 4.1). Heart failure and kidney disease use is not established under 18 (US 8.4; UK 4.2).
  • People at higher risk of ketoacidosis. The UK label names people with low beta cell reserve (for example low C-peptide or LADA, or a history of pancreatitis), restricted food intake or severe dehydration, reduced insulin doses, or higher insulin needs from illness, surgery or alcohol abuse, and says SGLT2 inhibitors "should be used with caution" in them (4.4).

Ketoacidosis

This is the warning to read twice. The US label says: "There have been postmarketing reports of fatal events of ketoacidosis in patients with type 2 diabetes mellitus using SGLT2 inhibitors, including FARXIGA", and that "Type 2 diabetes mellitus and pancreatic disorders (e.g., history of pancreatitis or pancreatic surgery) are also risk factors for ketoacidosis" (5.1). In the DECLARE trial, ketoacidosis was reported in 27 of 8,574 people on Farxiga against 12 of 8,569 on placebo (US 6.1); the UK label adds that 22 of the 27 were taking insulin at the time (4.8).

It can happen with near-normal glucose. "Blood glucose levels at presentation may be below those typically expected for diabetic ketoacidosis (e.g., less than 250 mg/dL)" (US 5.1). The UK label says presentation was atypical in a number of cases, "with only moderately increased blood glucose values, below 14 mmol/L (250 mg/dL)" (4.4).

Triggers named in the US label (5.1): "under-insulinization due to insulin dose reduction or missed insulin doses, acute febrile illness, reduced caloric intake, ketogenic diet, surgery, volume depletion, and alcohol abuse."

Symptoms. US 5.1: "nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath". The UK label lists nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness (4.4).

What to do. The US label says to "discontinue FARXIGA and seek medical attention immediately if signs and symptoms occur" (5.1). It can last longer than expected: urine glucose loss persists for 3 days after stopping, but there have been reports of ketoacidosis or glucosuria lasting more than 6 days and some up to 2 weeks after stopping an SGLT2 inhibitor (US 5.1). The UK label says restarting after ketoacidosis on an SGLT2 inhibitor "is not recommended, unless another clear precipitating factor is identified and resolved" (4.4). Your doctor may ask you to check ketones (US 17); for people in hospital, the UK label says blood ketone measurement is preferred to urine (4.4).

Genital and urinary infections, including Fournier's gangrene

Because more glucose passes in the urine, dapagliflozin "increases the risk of genitourinary infections including urinary tract infections and genital mycotic infections in both male and female patients" (US 5.3). In the US 12-trial pool, genital fungal infections affected 6.9% of women on 10 mg against 1.5% on placebo, and 2.7% of men against 0.3% (US Table 1). People with a history of genital fungal infection were more likely to get one during the trials than people without: 25.0% against 5.0% on 10 mg, and 10.0% against 0.8% on placebo (US 6.1). The UK label adds that phimosis has been reported with genital infections, in some cases needing circumcision (4.8).

Serious infections. The US label says serious genitourinary infections, "including urosepsis, pyelonephritis, and necrotizing fasciitis of the perineum (Fournier's gangrene, a rare life-threatening infection requiring urgent surgical intervention), have occurred in patients receiving SGLT2 inhibitors, including FARXIGA", and that in Fournier's gangrene "serious outcomes have included multiple surgeries and death" (5.3). The UK label lists Fournier's gangrene as very rare and adds: "Be aware that either uro-genital infection or perineal abscess may precede necrotising fasciitis" (4.4, 4.8). In DECLARE there were 6 cases in total, 1 on dapagliflozin and 5 on placebo (UK 4.8).

The warning signs (US 17): "pain or tenderness, redness, or swelling of the genitals or the area from the genitals back to the rectum, along with a fever above 100.4°F or malaise". The US label tells patients to "promptly seek medical attention" if these develop. If Fournier's gangrene is suspected, the drug is stopped and treated promptly (US 5.3; UK 4.4). The UK label also says a temporary pause should be considered while pyelonephritis or urosepsis is treated (4.4).

Side effects

Bar chart of genital fungal infections above placebo. Women: Jardiance 10 mg plus 3.9 points, Jardiance 25 mg plus 4.9, Farxiga 5 mg plus 6.9, Farxiga 10 mg plus 5.4. Men: Jardiance 10 mg plus 2.7, Jardiance 25 mg plus 1.2, Farxiga 5 mg plus 2.5, Farxiga 10 mg plus 2.4.
Figure 1. Extra genital fungal infections over placebo in each drug's own pooled diabetes trials (separate trials, not head to head). Source: Farxiga US label Table 1; Jardiance US label Table 2.
Adverse reaction (US Table 1)Placebo (n=1393)Farxiga 5 mg (n=1145)Farxiga 10 mg (n=1193)
Genital fungal infection, women1.5%8.4%6.9%
Nasopharyngitis6.2%6.6%6.3%
Urinary tract infection3.7%5.7%4.3%
Back pain3.2%3.1%4.2%
Increased urination1.7%2.9%3.8%
Genital fungal infection, men0.3%2.8%2.7%
Nausea2.4%2.8%2.5%
Influenza2.3%2.7%2.3%
Dyslipidaemia1.5%2.1%2.5%
Constipation1.5%2.2%1.9%
Discomfort with urination0.7%1.6%2.1%
Pain in extremity1.4%2.0%1.7%

Table 1 pools 12 placebo-controlled glucose control trials in adults with type 2 diabetes, 12 to 24 weeks long (mean exposure 21 weeks), and lists reactions in at least 2% on either dose that were more common than on placebo. The women's and men's rows are percentages of each sex. The US label says the overall safety profile was consistent across uses, and no new adverse reactions were found in the DAPA-HF, DELIVER and DAPA-CKD trials (6.1).

Other findings in the labels. Haematocrit rose by 2.30% on 10 mg against a 0.33% fall on placebo by week 24 (US 6.1); the UK label says people with pronounced rises should be investigated for an underlying blood disorder (4.4). Volume depletion events in the 13-trial pool affected 1.1% on 10 mg and 0.7% on placebo (US Table 2). Serious allergic reactions, severe skin reactions and angioedema were reported in 0.3% on Farxiga and 0.2% on comparators (US 6.1). In people with moderate kidney impairment, raised parathyroid hormone and low blood pressure were more common than on placebo (UK 4.4).

Reports after approval (US 6.2, no reliable frequency): Fournier's gangrene, urosepsis and pyelonephritis; ketoacidosis; acute kidney injury; rash. The UK label also lists, as very rare, angioedema and tubulointerstitial nephritis (4.8).

What the outcome trials showed

Forest plot of hazard ratios versus placebo. Jardiance EMPA-REG MACE 0.86 (0.74 to 0.99). Farxiga DECLARE MACE 0.93 (0.84 to 1.03), not significant. Farxiga DECLARE heart failure admission or CV death 0.83 (0.73 to 0.95). Jardiance EMPEROR-Reduced 0.75 (0.65 to 0.86). Farxiga DAPA-HF 0.74 (0.65 to 0.85). Jardiance EMPEROR-Preserved 0.79 (0.69 to 0.90). Farxiga DELIVER 0.82 (0.73 to 0.92). Jardiance EMPA-KIDNEY 0.72 (0.64 to 0.82). Farxiga DAPA-CKD 0.61 (0.51 to 0.72).
Figure 2. Primary results of the Farxiga and Jardiance outcome trials, each against its own placebo (separate trials, not head to head). Source: Farxiga and Jardiance US prescribing information, section 14.
Trial (US label section)Who took partMain result, Farxiga 10 mg vs placebo
DECLARE (14.3)17,160 adults with type 2 diabetes and either established cardiovascular disease or two or more extra risk factors; median 4.2 yearsHeart failure admission or cardiovascular death 4.9% vs 5.8% (HR 0.83), driven by fewer heart failure admissions (HR 0.73), with no change in cardiovascular death. Heart attack, stroke or cardiovascular death 8.8% vs 9.4% (HR 0.93, not significant)
DAPA-CKD (14.4)4,304 adults with chronic kidney disease (eGFR 25 to 75, with albuminuria), 68% with type 2 diabetes; median 28.5 months50% or more sustained eGFR decline, end-stage kidney disease, or cardiovascular or kidney death: 197 vs 312 patients (HR 0.61). All-cause death HR 0.69
DAPA-HF (14.5)4,744 adults with heart failure and ejection fraction 40% or less; median 18 monthsCardiovascular death, heart failure admission or urgent heart failure visit: 386 vs 502 patients (HR 0.74)
DELIVER (14.5)6,263 adults aged 40 and over with heart failure and ejection fraction above 40%; median 28 monthsSame endpoint: 512 vs 610 patients (HR 0.82)

DAPA-CKD excluded polycystic kidney disease, lupus nephritis and ANCA-associated vasculitis, and people on recent immunosuppressive therapy (US 14.4). The UK label says there is no experience in chronic kidney disease in people without diabetes who do not have albuminuria (4.4). Each result is against placebo added to standard care; these trials do not tell you whether dapagliflozin is better than another SGLT2 inhibitor. Our Jardiance vs Farxiga guide sets the two sets of trials side by side.

When to get urgent help

Get medical help straight away, or call emergency services, if you have:

  • Signs of ketoacidosis: nausea, vomiting, stomach pain, tiredness or labored breathing (US 17), and in the UK label's list also excessive thirst, confusion and unusual fatigue or sleepiness (4.4), even if your blood glucose is normal or only a little high. Stop Forxiga and seek medical attention immediately (US 5.1, 17). Ketoacidosis needs hospital treatment (US Medication Guide).
  • Pain or tenderness, redness or swelling of the genitals or the area from the genitals back to the rectum, with a fever above 100.4°F (38°C) or feeling very unwell. These can be signs of Fournier's gangrene, which needs urgent surgery (US 5.3, 17).
  • Urinary infection symptoms with fever, back pain, nausea or vomiting (US Medication Guide). Serious urinary infections, including kidney infection (pyelonephritis) and urosepsis, have occurred on SGLT2 inhibitors (US 5.3).
  • Rash, hives, or swelling of the face, lips, tongue or throat that may cause trouble breathing or swallowing. Stop Forxiga and contact your healthcare provider or go to the nearest hospital emergency room right away (US Medication Guide). Anaphylaxis and angioedema have been reported (US 4).
  • Dizziness, fainting, light-headedness or weakness, especially on standing, which the US Medication Guide links to dehydration; acute kidney injury has been reported, some cases needing hospital care and dialysis (US 5.2).
  • Low blood sugar that does not improve, if you also take insulin or a sulfonylurea (US 5.4).
  • Taking too much: call your healthcare provider or the US Poison Help line on 1-800-222-1222, or go to the nearest emergency room right away (US Medication Guide). In Australia, the Poisons Information Centre is 13 11 26 (our addition). No overdose was reported in the US clinical programme, and removal by haemodialysis has not been studied (US 10).

Tell the medical staff that you take dapagliflozin (Forxiga or Farxiga), how much and when you last took it, because ketoacidosis on this medicine can be missed when blood glucose is not very high.

Who should not take Forxiga 10mg

Never take it if:

  • you have had a serious allergic reaction to dapagliflozin or any ingredient of the tablet. The US label contraindicates it after "a history of a serious hypersensitivity reaction" and notes that anaphylaxis and angioedema have been reported (4); the UK label contraindicates it in hypersensitivity to the active substance or any excipient (4.3). This is the only contraindication in both labels.

Not recommended, should not be used, or only with care:

  • Type 1 diabetes: US: "not recommended for use to improve glycemic control" (1); UK: "should not be used for treatment of patients with type 1 diabetes" (4.4).
  • Type 2 diabetes with an eGFR below 45, for glucose control: not recommended in the US label and likely to be ineffective (1, 2.2). Kidney disease and heart failure use follows the separate eGFR rules above.
  • Starting treatment with a low eGFR: US: not recommended below 25 (2.3); UK: not recommended below 15 (4.2).
  • Kidney disease from polycystic kidney disease, or with recent immunosuppressive therapy for kidney disease: not recommended for the kidney disease indication (US 1).
  • Pregnancy: US: "not recommended during the second and third trimesters of pregnancy", based on animal kidney findings (8.1). UK: not recommended in the second and third trimesters, and "When pregnancy is detected, treatment with dapagliflozin should be discontinued" (4.6). Tell your doctor straight away if you are or may be pregnant, or plan a pregnancy (US 17).
  • Breastfeeding: US: "use of FARXIGA is not recommended while breastfeeding" (8.2). UK: "Dapagliflozin should not be used while breast-feeding" (4.6).
  • Previous ketoacidosis on an SGLT2 inhibitor: UK: restarting is not recommended unless another clear trigger is found and resolved (4.4).
  • Rare sugar intolerances: each UK Forxiga 10 mg tablet contains 50 mg lactose, and the UK label says people with galactose intolerance, total lactase deficiency or glucose-galactose malabsorption "should not take this medicinal product" (2, 4.4). The US tablet also contains anhydrous lactose (US 11). We have not confirmed the excipients of the Indian pack, so read the carton.
  • Children under 10: safety and effectiveness for glucose control are not established (US 8.4).
  • Before major surgery, during acute serious illness, or when you cannot eat or drink: it is withheld or interrupted (US 2.4, 5.1; UK 4.4).

Medicines that interact

  • Insulin and sulfonylureas (for example glimepiride): higher risk of low blood sugar; lower doses of these may be needed (US Table 4; UK 4.5).
  • Diuretics: dapagliflozin "may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension" (UK 4.5).
  • Lithium: lithium levels may fall; the US label says monitor lithium more often when starting dapagliflozin or changing the dose (Table 4), and the UK label says refer the patient to the lithium prescriber for monitoring (4.5).
  • Rifampicin and mefenamic acid: rifampicin lowered dapagliflozin exposure by 22% and mefenamic acid raised it by 55%, with no clinically meaningful change in urine glucose; no dose change is recommended (UK 4.5).
  • Urine glucose and 1,5-AG tests: not reliable while you take it (US Table 4).

In the label interaction studies, metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan and simvastatin needed no dapagliflozin dose change (US Table 5; UK 4.5). Tell your doctor or pharmacist about every medicine and supplement you take.

Prescription and legal status

In the US, Farxiga (NDA 202293) and generic dapagliflozin are prescription medicines, and the FDA says personal importation of unapproved medicines is illegal in most circumstances. In the UK, Forxiga 10 mg (AstraZeneca UK, PLGB 17901/0325) is a prescription-only medicine (POM). In Australia, Forxiga 10 mg is registered (AUST R 180147), Schedule 4 (Prescription Only Medicine) and on the PBS (healthdirect, PBS verified 1 October 2026). In Canada, Forxiga 10 mg (DIN 02435470) has been marketed as a prescription medicine since 16 January 2015 (Health Canada Drug Product Database, checked 3 November 2026). In India, Tata 1mg and Medkart mark Forxiga 10mg as prescription required, and the carton in our product photo carries the Rx symbol. Check the rules where you live.

Buying genuine Forxiga

The MHRA warns that "Any medicine not authorised for sale in the UK can be unsafe or ineffective and there is no way of knowing what is in them or the negative health effects they can have", and it advises UK buyers to "Only use UK-registered pharmacies, including online pharmacies displaying the official green cross logo". That warning covers this Indian Forxiga pack. When your order arrives, read the carton and strips: they should say Forxiga and dapagliflozin 10 mg, name AstraZeneca, and carry a batch number and expiry date. These checks cannot prove that tablets are genuine, because counterfeiters copy packaging. If a batch causes unusual symptoms, seek medical advice and report it to your medicines regulator (the MHRA Yellow Card scheme in the UK, FDA MedWatch in the US, the TGA in Australia or Health Canada) as well as to us.

Storage. The US label says store at 20 to 25°C, with excursions from 15 to 30°C permitted (16); the UK label says no special storage conditions are needed (6.4). For the Indian pack, Tata 1mg gives "Store below 30°C", PharmEasy a cool and dry place protected from sunlight and moisture, and Medkart room temperature. No refrigeration is needed. Keep it out of the reach of children.

Delivery

We ship Forxiga 10mg to the US, UK, Australia and Canada in plain packaging with tracking. Standard delivery takes 7 to 14 business days. Shipping costs a flat $25 on orders under $149 and is free from $149. Order well before your current supply runs out, and do not stop or ration your tablets while you wait, especially if you take it for heart failure or kidney disease. See our shipping page and refund policy.

Related guides

Sources

  • FARXIGA (dapagliflozin tablets), US prescribing information and Medication Guide, AstraZeneca Pharmaceuticals LP, Medication Guide revised 06/2026 (DailyMed setid 72ad22ae-efe6-4cd6-a302-98aaee423d69, SPL version 49, published 11 September 2026): sections 1, 2.1 to 2.5, 3, 4, 5.1 to 5.4, 6.1 (Tables 1 to 3), 6.2, 7 (Table 4), 8.1, 8.2, 8.4 to 8.7, 10, 11, 12.1 to 12.3 (Table 5), 14.1 (Table 7), 14.3 to 14.5 (Tables 15 to 17), 16, 17. DailyMed
  • Forxiga 10 mg film-coated tablets, UK Summary of Product Characteristics, AstraZeneca UK Limited, PLGB 17901/0325, text revised 10/07/2026 (emc 7607): sections 2, 3, 4.1 to 4.9, 5.1, 6.1, 6.4, 6.5. emc
  • Dapagliflozin tablets, US generic labels: Teva Pharmaceuticals (DailyMed setid 0406a1c0-56b1-4ea1-95ae-00357ac1ba7e, version 8) and Lupin Pharmaceuticals (setid 08baca21-e39e-4e61-961f-d89432fe8007, version 15), section 1. DailyMed
  • US Food and Drug Administration. FDA approves first generic dapagliflozin tablets, 7 April 2026. FDA
  • Drugs@FDA, NDA 202293 Farxiga (AstraZeneca AB): original approval 8 January 2014, 5 mg and 10 mg, prescription; checked 3 November 2026. Drugs@FDA
  • Centers for Medicare and Medicaid Services. National Average Drug Acquisition Cost (NADAC) 2026, file as of 4 November 2026: Farxiga 10 mg tablet $12.07647 (NDCs 00310621030, 00310621039, 00310621090), effective 21 October 2026; generic dapagliflozin 10 mg tablet $0.18445 (21 NDC rows), effective 21 October 2026 (NDC 72205043302 effective 28 October 2026). data.medicaid.gov
  • Centers for Medicare and Medicaid Services. Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026: Farxiga $178.50 negotiated price and $556.00 list price for a 30-day supply. CMS
  • NHS Business Services Authority, dm+d: Dapagliflozin 10mg tablets 28 tablet, Drug Tariff Part VIIIA Category M, 232p from 1 October 2026; checked 3 November 2026. NHSBSA dm+d; Community Pharmacy England. Dapagliflozin tablets: new reimbursement prices from September 2025 (Category C to Category M). CPE
  • healthdirect Australia, Forxiga: Schedule 4, PBS verified 1 October 2026; Australian Commission on Safety and Quality in Health Care Medicine Finder, Forxiga AUST R 180147. healthdirect
  • Health Canada Drug Product Database: Forxiga 10 mg, DIN 02435470, AstraZeneca Canada, marketed since 16 January 2015, prescription; checked 3 November 2026. Health Canada
  • Indian pharmacy listings for Forxiga 10mg (Tata 1mg, PharmEasy, Medkart), checked 3 November 2026.
  • MHRA. 20 million illegal erectile dysfunction pills seized as MHRA warns against risky online buys, 13 February 2026. GOV.UK
  • US Food and Drug Administration. Personal Importation. FDA

This page is for information and is not medical advice. Forxiga is a prescription medicine for type 2 diabetes, heart failure and chronic kidney disease. Take it only as prescribed by a doctor who checks your kidney function, and do not start, stop or switch it without your doctor.

Frequently asked questions

What is Forxiga 10mg?

Forxiga 10mg is AstraZeneca's dapagliflozin 10 mg film-coated tablet, sold here in its Indian pack (Tata 1mg, PharmEasy and Medkart name AstraZeneca). Dapagliflozin is an SGLT2 inhibitor that makes the kidneys pass more glucose into the urine. In the US the same medicine is sold as Farxiga. Its licensed uses are type 2 diabetes, heart failure and chronic kidney disease in adults, and glucose control in type 2 diabetes from age 10 (US label 1; UK label 4.1).

Is Forxiga the same as Farxiga?

Yes, they are the same AstraZeneca medicine with the same active ingredient, dapagliflozin. Farxiga is the US brand name; Forxiga is used in the UK, Europe, Australia, Canada and India. Our Indian Forxiga pack is not registered with the FDA, MHRA, TGA or Health Canada, so no regulator in those countries has reviewed this particular pack. We have not confirmed the tablet markings on the Indian pack.

How much does Forxiga 10mg cost per tablet?

As of November 2026, $3.14 a tablet in the 28 pack ($88), $2.82 in the 56 pack ($158) and $2.54 in the 84 pack ($213), before shipping. Shipping is $25 under $149 and free from $149, so the 28 pack works out at $4.04 a tablet with shipping. The pack selector shows the current price. US pharmacies pay about $0.18 a tablet for generic dapagliflozin 10 mg (NADAC, effective 21 October 2026), so US buyers with a prescription should compare local generic prices first. At one tablet a day, the 28, 56 and 84 packs last 4, 8 and 12 weeks (our arithmetic).

Is there a generic Farxiga in the US?

Yes. The FDA approved the first generic dapagliflozin tablets on 7 April 2026, and the NADAC file as of 4 November 2026 lists 21 generic 10 mg NDC rows at $0.18445 a tablet, against $12.07647 for Farxiga 10 mg. The Teva and Lupin generic labels we checked list glucose control and heart failure admission risk reduction in adults with type 2 diabetes, but not the kidney disease or heart failure indications. Ask your doctor or pharmacist what that means for your prescription.

How do I take Forxiga 10mg?

One tablet once a day, with or without food, swallowed whole (US label 12.3; UK label 4.2). Your doctor should check your kidney function and fluid status first (US 2.1). If you miss a dose, take it as soon as you remember, but do not take two doses at the same time (US 2.5). Drink enough fluid, and stop it for at least 3 days before surgery or prolonged fasting if possible, as your doctor advises (US 2.4).

Should I take Forxiga 5mg or 10mg?

Your doctor decides. In the US label, 10 mg is the dose for chronic kidney disease, heart failure and heart failure risk reduction in type 2 diabetes, while glucose control starts at 5 mg and can go up to 10 mg (2.2, 2.3). The UK label uses 10 mg for all its uses, with a 5 mg start only in severe liver impairment (4.2). There is no labelled dose above 10 mg.

Does Forxiga work if my kidney function is low?

For glucose control, the US label does not recommend it below an eGFR of 45 because it is likely to be ineffective. For kidney disease and heart failure, the US label does not recommend starting it below an eGFR of 25, but people already taking it may continue 10 mg if the eGFR falls below 25 (US 2.3). The UK label does not recommend starting below an eGFR of 15 (4.2). The labels differ, so this is your doctor's call.

What are the side effects of Forxiga 10mg?

In the US pooled diabetes trials, the most common were genital fungal infections (6.9% of women on 10 mg vs 1.5% on placebo; 2.7% of men vs 0.3%), nasopharyngitis, urinary tract infections, back pain and passing more urine (US Table 1). Serious risks include ketoacidosis, which can occur with near-normal blood glucose, Fournier's gangrene, dehydration and low blood pressure, acute kidney injury, and low blood sugar when taken with insulin or a sulfonylurea (US 5.1 to 5.4).

Who should not take Forxiga?

Anyone who has had a serious allergic reaction to dapagliflozin or an ingredient of the tablet (US 4; UK 4.3). It is not a type 1 diabetes medicine (US 1; UK 4.4). It is not recommended in the second and third trimesters of pregnancy or while breastfeeding (US 8.1, 8.2; UK 4.6), and the UK label says restarting it after ketoacidosis on an SGLT2 inhibitor is not recommended unless another clear precipitating factor is identified and resolved (4.4). The UK tablet contains lactose (4.4).

Do I need a prescription for Forxiga?

Yes, in the countries we ship to. Farxiga and generic dapagliflozin are prescription medicines in the US, Forxiga is POM in the UK, Schedule 4 in Australia and a prescription medicine in Canada. Indian listings (Tata 1mg, Medkart) also mark it as prescription required. The FDA says personal importation of unapproved medicines is illegal in most circumstances, and the MHRA advises UK buyers to use only UK-registered pharmacies.

How long does delivery of Forxiga 10mg take?

Standard delivery to the US, UK, Australia and Canada takes 7 to 14 business days, in plain packaging with tracking. Shipping is $25 on orders under $149 and free from $149. If you already take dapagliflozin, order well before your supply runs out and do not stop or ration your tablets while you wait, especially if you take it for heart failure or kidney disease.

Guide to Type 2 DiabetesAn evidence-based guide to type 2 diabetes medicines: how metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors and combination tablets differ on dosing, side effects and cost.

Related articles

Customer Reviews

No reviews yet. Bought Forxiga 10mg? Tell other buyers how it went.